Overview of Stem Cell Therapy at New Jersey Pain Management Clinics
http://nj-pain.com/treatments/stem-cell-procedure/ Stem Cell Therapy falls under regenerative medicine, and it is now a reality in musculoskeletal medicine. This includes stem cells being...
By: New Jersey Pain Network
See original here:
Overview of Stem Cell Therapy at New Jersey Pain Management Clinics - Video
Dr Sherif Stem cell therapy on OA
lecture powerpoint.
By: Medical Center
Go here to see the original:
Dr Sherif Stem cell therapy on OA - Video
A Winnipeg-based company that has touted its ability to improve the lives of Multiple Sclerosis patients through stem cell therapy is now under the microscope after allegations of fraud from a client.
The CEO of Regenetek Research Inc. has been collecting thousands of dollars from Canadian patients looking for help. Some of the patients are now questioning the research and credentials of the man they know as Dr. Doug.
One of them is Lee Chuckry, 47. He has been living with MS for nearly two decades.
MS just keeps progressing, thats what it does. Hopefully I could stop it. That was my ultimate goal, Chuckry said in an interview with CTV News.
His efforts led him to Regenetek, and its CEO: Doug Broeska.
In testimonials, MS patients attributed miraculous medical improvement to experimental stem cell therapy. For $35,000, Regenetek patients were flown to India for the procedure.
Chuckry was one of the participants. But when he returned home, he says his symptoms worsened.
When he started digging deeper, he said, he found the doctor hed put his faith in wasnt what he claimed to be.
Im going to call Doug a con artist, Chuckry said. You are preying on people who are desperate. They are looking for hope of any sort.
Chuckry and at least one other patient have gone to the RCMP. They allege Broeska, who claims to hold a PhD and a Bachelor of Science, is a fraud who is operating as a medical researcher without proper credentials.
Original post:
Winnipeg company offering stem cell therapy is fraudulent, MS sufferer alleges
[SPEED] Embryonic Stem Cells
Thanks for watching! Hope it helped somebody! If you would like more videos on a certain topic, let me know in the comments below. I do not own these videos. I have simply sped them up for...
By: Speed Science
Read more:
[SPEED] Embryonic Stem Cells - Video
The birth and engraftment of a blood stem cell | Boston Children #39;s Hospital
When a patient receives a bone marrow transplant, the transplanted blood stem cells find their home, begin dividing and establish themselves in the body much like natural blood stem cells do....
By: Boston Children #39;s Hospital
Read the original post:
The birth and engraftment of a blood stem cell | Boston Children's Hospital - Video
How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell
http://www.nextgenerationstemcell.com Stem Cell Therapy Stem Cell Research.
By: Jasen Kobobel
See the article here:
How Can Stem Cell Therapy Help PRP (Platelet Rich Plasma) - Next Generation Stem Cell - Video
Cancer stem cells and successful and potential treatments
Robert Rees answers questions on cancer stem cells and successful and potential treatments, including antibody therapy and vaccine based immunotherapy. http:...
By: Oxford Academic (Oxford University Press)
More here:
Cancer stem cells and successful and potential treatments - Video
Live100 Hospitals - Stem Cell Therapy
"We wanted to focus on stem cell after seeing the advantages since the cells were available in the body and they were really doing wonderful research across the world which was really promising...
By: Live100 Hospitals
Read this article:
Live100 Hospitals - Stem Cell Therapy - Video
Researchers at the Stanford University School of Medicine have discovered the stem cell in mice that gives rise to bone, cartilage and a key part of bone marrow called the stroma.
In addition, the researchers have charted the chemical signals that can create skeletal stem cells and steer their development into each of these specific tissues. The discovery sets the stage for a wide range of potential therapies for skeletal disorders such as bone fractures, brittle bones, osteosarcoma or damaged cartilage.
A paper describing the findings will be published Jan. 15 in Cell.
"Millions of times a year, orthopedic surgeons see torn cartilage in a joint and have to take it out because cartilage doesn't heal well, but that lack of cartilage predisposes the patient to arthritis down the road," said Michael Longaker, MD, a professor of plastic and reconstructive surgery at Stanford and a senior author of the paper. "This research raises the possibility that we can create new skeletal stem cells from patients' own tissues and use them to grow new cartilage." Longaker is also co-director of the Stanford Institute for Stem Cell Biology and Regenerative Medicine.
An intensive search
The researchers started by focusing on groups of cells that divide rapidly at the ends of mouse bones, and then showed that these collections of cells could form all parts of bone: the bone itself, cartilage and the stroma -- the spongy tissue at the center of bones that helps hematopoietic stem cells turn into blood and immune cells. Through extensive effort, they then identified a single type of cell that could, by itself, form all these elements of the skeleton.
The scientists then went much further, mapping the developmental tree of skeletal stem cells to track exactly how they changed into intermediate progenitor cells and eventually each type of skeletal tissue.
"Mapping the tree led to an in-depth understanding of all the genetic switches that have to be flipped in order to give rise to more specific progenitors and eventually highly specialized cells," said postdoctoral scholar Charles Chan, PhD, who shares lead authorship of the paper with postdoctoral scholar David Lo, MD, graduate student James Chen and research assistant Elly Eun Young Seo. With that information, the researchers were able to find factors that, when provided in the right amount and at the right time, would steer the development of skeletal stem cells into bone, cartilage or stromal cells.
"If this is translated into humans, we then have a way to isolate skeletal stem cells and rescue cartilage from wear and tear or aging, repair bones that have nonhealing fractures and renew the bone marrow niche in those who have had it damaged in one way or another," said Irving Weissman, MD, professor of pathology and of developmental biology, who directs the Stanford Institute for Stem Cell Biology and Regenerative Medicine. Weissman, the other senior author of the paper, also holds the Virginia and Daniel K. Ludwig Professorship in Clinical Investigation in Cancer Research.
Reprogramming fat cells
Excerpt from:
Stanford researchers isolate stem cell that gives rise to bones, cartilage in mice
Do you use stem cells in regenerative medicine? - prof. Graziella Pellegrini
By: Bio-Tech Media
The rest is here:
Do you use stem cells in regenerative medicine? - prof. Graziella Pellegrini - Video
MIAMI (PRWEB) January 14, 2015
Citing fast-paced growth and the need for more space to accommodate its expanding operations, Global Stem Cells Group CEO Benito Novas has announced plans to move the organizations headquarters from Sunrise, Florida to the Miami Lakes Corporate Center. The new location more than doubles the space for the international stem cell and regenerative medicine company's corporate offices.
Since opening in 2012 under the Regenestem brand, Global Stem Cells Group and its six operating companies have grown exponentially, establishing partnerships with stem cell clinics, hospitals, researchers and physicians in the Philippines, South America and Europe.
The new Global Stem Cells Group facility provides state-of-the-art space for our entire team to drive innovation through our research and development initiatives, and support partnering activities with our biotechnology products and education programs, Novas says. We now have the space to continue the fast-paced growth of our companies and advance the development of new stem cell and regenerative medicine technologies that will benefit patients worldwide.
The new corporate headquarters, scheduled to open January 15, 2015, are located in the Miami Lakes Corporate Center, 14750 NW 77th Court, Suite 304 Miami Lakes, FL 33016.
For more information visit the Global Stem Cells website, email bnovas(at)regenestem(dot)com, or call 305-224-1858.
About the Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Groups corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
See the original post:
Global Stem Cells Group to Move Headquarters to Larger Miami Lakes Office Complex
Contact Information
Available for logged-in reporters only
Newswise January 13, 2015 New York, NY Peter S. Kim has been named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford University School of Medicine. Established in 1994, Ludwig professorships have since been awarded to a total of 15 leading scientists at academic institutions affiliated with the six U.S.-based Ludwig Centers. With this appointment Kim also becomes a member of the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford.
Kims lab focuses on the mechanisms by which viral membranes fuse with cell membranes, which has to happen for the virus to invade its target cell. His team also studies how that process might be disrupted by small molecules and antibodies. Kims lab is, for example, using such studies to engineer antigens for a vaccine that might elicit antibodies that block a key step in HIVs invasion of its target cell. The strategies that he is developing could be applied to design new preventive and therapeutic vaccines for cancers. His lab is also developing methods to identify small molecules that bind tightly and very specifically to proteins that have so far proved resistant to targeting by typical drug-like molecules.
Kim joined Stanford University in February 2014 after a ten-year tenure as president of Merck Research Laboratories, Merck & Co., Inc. During this time he oversaw the development and FDA approval of Gardasil, the worlds first vaccine against HPV, the causative agent of cervical cancer. Kim began his academic career as a professor in the biology department at MIT, where he ultimately served as associate head. During his 16 years at MIT Kim was also an investigator of the Howard Hughes Medical Institute and a member of the Whitehead Institute for Biomedical Research.
We are very happy, and fortunate, to have Peter Kim back here at Stanford, where he began his graduate training, said Irv Weissman, director of the Ludwig Center for Cancer Stem Cell Research and Medicine at Stanford. Peter brings with him rare experience and new strategies for developing preventive tools and therapiesincluding immunotherapiesfor viral infections that cause, allow and/or infect cancers. His goals are in line with our mission, and his approaches complement our own efforts to recruit the immune system to attack cancer cells.
Kim has received numerous awards for his research and holds leadership positions at several academic and scientific institutions. He is a member of the National Academy of Sciences and the Institute of Medicine and a fellow of the American Academy of Arts and Sciences. He serves on the Scientific Review Board of the Howard Hughes Medical Institute, the External Scientific Advisory Board of the Harvard Program in Therapeutic Science, the Board of Scientific Governors of the Scripps Research Institute and the Scientific Advisory Working Group of the Vaccine Research Center, NIAID, NIH.
Kim joins four other Virginia and D.K. Ludwig Professors at Stanford: Lucy Shapiro, Irving Weissman, Sanjiv Sam Gambhir and Roeland Nusse.
# # #
About Ludwig Cancer Research Ludwig Cancer Research is an international collaborative network of acclaimed scientists that has pioneered cancer discoveries for more than 40 years. Ludwig combines basic research with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested more than $2.5 billion in life-changing cancer research through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.
See more here:
Peter S. Kim Named the Virginia and D.K. Ludwig Professor of Biochemistry at Stanford
Stem Cell Therapy: A cure for Diabetes | PlacidWay
http://tiny.cc/DiabetesCure2015 Diabetes treatment can consist of numerous elements, consisting of standard medications, alternative medication, and natural treatments. Alternative therapies...
By: Robert Esser
Continued here:
Stem Cell Therapy: A cure for Diabetes | PlacidWay - Video
Modelling Neurodegenerative Diseases with Stem Cells - Maya Mitalipova
Source - http://serious-science.org/videos/1801 MIT Professor Maya Mitalipova on age-related diseases, stem cells, and new ways to model neurodegenerative diseases.
By: SeriousScience
See the rest here:
Modelling Neurodegenerative Diseases with Stem Cells - Maya Mitalipova - Video
Stem Cell Therapy for Diabetes
THE ONLY NATURAL TREATMENT FOR DIABETES THAT REALLY CURES DIABETES AND REALLY WORKS!!! Stem Cell Therapy for Diabetes Diabetes has been one of those diseases which cause ...
By: Robert Esser
Read more here:
Stem Cell Therapy for Diabetes - Video
IMAGE:This is the cover for Stem Cells, Tissue Engineering and Regenerative Medicine. view more
Credit: World Scientific, 2015
In his latest book published by World Scientific, Professor David Warburton from The Saban Research Institute of Children's Hospital Los Angeles and the University of Southern California presents a collection of essays on the current state of the regenerative medicine and stem cell research field.
Entitled Stem Cells, Tissue Engineering and Regenerative Medicine, this up-to-date compendium surveys current issues in stem cell biology and regenerative medicine. Topics range from key concepts in regenerative medicine to the newest progenitor cell therapies for organ systems, to advice on how to set up a pluripotent stem cell laboratory.
Overviews of the most recent progress in stem cell research describe work that is in the pre-clinical pipeline from scientists working at The Saban Research Institute of Children's Hospital Los Angeles and colleagues around the world.
"The book addresses some of the big questions faced by researchers in the field of stem cell biology and regenerative medicine," said Professor Warburton. "Those of us working in this field in California are positively impacted by the critical funding provided by the citizens of the state through the California Institute for Regenerative Medicine. I believe this book shows that the hope behind CIRM - the hope that stem cells can really revolutionize medicine and human health - is fully justified."
A global collection of essays from collaborating investigators in Australia, Brazil, Iran, Taiwan and the United Kingdom, as well as across the United States. This book will describe diverse regenerative medicine solutions for airways, cancer, craniofacial structures, intestine, heart, kidney, liver, lung and nervous system. These advances are placed in the context of the overall field, providing an investigator-level overview which will be accessible to the educated scientific generalist as well as a college-educated readership, scientific writers, educators and professionals of all kinds.
###
Professor Warburton's research is supported by the California Institute for Regenerative Medicine, the National Institutes of Health: National Heart, Lung and Blood Institute, National Institute of Environmental Health Sciences, Fogarty International Center, National Institute of General Medical Sciences, The Pasadena Guild of Children's Hospital Los Angeles, The Santa Anita Foundation, The Webb Foundation, The Garland Foundation and anonymous venture philanthropy.
The book retails for US$155/ 102 (hardcover). More information on the book can be found at http://www.worldscientific.com/worldscibooks/10.1142/9212.
See the article here:
Renowned professor's book addresses stem cell biology & regenerative medicine
IMAGE:BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal... view more
Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, January 12, 2014--A promising new therapeutic approach to treat a variety of diseases involves taking a patient's own cells, turning them into stem cells, and then deriving targeted cell types such as muscle or nerve cells to return to the patient to repair damaged tissues and organs. But the clinical effectiveness of these stem cells has only been modest, which may be due to the advanced age of the patients or the effects of chronic diseases such as diabetes and cardiovascular disease, according to a probing Review article published in BioResearch Open Access, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers . The article is available on the BioResearch Open Access website.
Anastasia Yu. Efimenko, TN Kochegura, ZA Akopyan, and YV Parfyonova, Moscow State University (Russia), analyze how aging and chronic diseases might affect the regenerative potential of autologous stem cells and explain the differences between the promising results reported in preclinical studies using stem cells derived from healthy young donors and the more modest success of clinical studies in aged patients. The authors propose strategies to test for and enhance to regenerative properties and therapeutic potential of stem cells in the article "Autologous Stem Cell Therapy: How Aging and Chronic Diseases Affect Stem and Progenitor Cells".
"This review discusses a very important issue in regenerative medicine, how aging and chronic pathologies such as cardiovascular diseases and metabolic disorders affect adult stem/progenitor cells," says BioResearch Open Access Editor Jane Taylor, PhD, MRC Centre for Regenerative Medicine, University of Edinburgh, Scotland. "Future therapies are discussed by the authors in terms of overcoming or correcting the limitations of these cells in order to enhance their therapeutic potential."
###
About the Journal
BioResearch Open Access is a bimonthly peer-reviewed open access journal led by Editor-in-Chief Robert Lanza, MD, Chief Scientific Officer, Advanced Cell Technology, Inc. and Editor Jane Taylor, PhD. The Journal provides a new rapid-publication forum for a broad range of scientific topics including molecular and cellular biology, tissue engineering and biomaterials, bioengineering, regenerative medicine, stem cells, gene therapy, systems biology, genetics, biochemistry, virology, microbiology, and neuroscience. All articles are published within 4 weeks of acceptance and are fully open access and posted on PubMed Central. All journal content is available on the BioResearch Open Access website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including DNA and Cell Biology, Tissue Engineering, Stem Cells and Development, Human Gene Therapy, HGT Methods, and HGT Clinical Development, and AIDS Research and Human Retroviruses. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
More here:
Is stem cell therapy less effective in older patients with chronic diseases?
Novel cancer stem cells glioma cell invasion - Dr Paul Brennan
Dr Paul Brennan, University of Edinburgh, talks about his research into the identification of a novel cancer stem cell that might be important for glioma cel...
By: acmedsci
See original here:
Novel cancer stem cells & glioma cell invasion - Dr Paul Brennan - Video
Jeunesse Global Revolutionary Anti Aging Skin Care with Stem Cells
By: Karina Palmer
See the article here:
Jeunesse Global Revolutionary Anti Aging Skin Care with Stem Cells - Video
Stem Cells Dr. Newman
Dr Newman is the innovator who formulated our anti-aging skin care line. Watch as he answers some inportant questions regarding the stem cell skin care. Feel free to contact me for more informatio...
By: Jeff Valentine
Go here to read the rest:
Stem Cells Dr. Newman - Video